Presentation is loading. Please wait.

Presentation is loading. Please wait.

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

Published byRhoda Norris Modified over 5 years ago

Similar presentations

Presentation on theme: "Axl Receptor Axis: A New Therapeutic Target in Lung Cancer"— Presentation transcript:

1 Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Pavel A. Levin, MD, PhD, Rolf A. Brekken, PhD, Lauren Averett Byers, MD, John V. Heymach, MD, PhD, David E. Gerber, MD  Journal of Thoracic Oncology  Volume 11, Issue 8, Pages (August 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Axl signaling and regulation. Upper panel: Axl signlaling. (A) Axl signaling includes three well-described pathways: (1) Ras/Raf/MEK/ERK, (2) Elmo1/2/DOCK1/Rac1/Pak, and (3) Gab2/PI3K/Akt. These pathways promote cancer cell proliferation, migration, and survival. (B–F) Patterns of Axl activation, including ligand-dependent activation through interaction with Gas6 (B) and ligand-independent activation either through Axl transcellular homophilic binding and adhesion (C), overexpression (D), interaction with another TAM family member receptor (Tyro3) (E), or heterodimerization with a non-TAM family receptor such as EGFR (F). Lower panel: Axl regulation. Axl synthesis from DNA to mRNA to protein is regulated at each step by transcription factor activation, DNA methylation, RNA interference, and protein folding. Ap1, activated protein 1; Chr 19, chromosome 19; DOCK1, dedicator of cytokinesis 1; EGFR, epithelial growth factor receptor; Elmo 1/2, engulfment and cell motility protein 1 and 2; ERK, extracellular signal regulated kinase; FNIII, fibronectin III; Gab2, GRB2-associated binding protein 2; Gas6, growth arrest-specific 6; Grb2, growth factor receptor-bound protein 2; HIF1, hypoxia-inducible factor 1; HSP90, heat shock protein 90; Ig, immunoglobulin; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; MZF1, myeloid zinc finger 1; PAK, p21 protein-activated kinase; PI3K, phosphoinositide-3 kinase (consists of p85 and p110 subunits); PIP2, phosphatidylinositol (3,4)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; Rac1, Rho-family small GTP-binding protein 1; SOS, son of sevenless; SP1 and SP3, specificity protein 1 and 3; YAP1, yes-associated protein 1. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Axl Receptor Axis: A New Therapeutic Target in Lung Cancer"

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M

Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M
John W. Bloom, MD  Journal of Allergy and Clinical Immunology 

John W. Bloom, MD  Journal of Allergy and Clinical Immunology 
Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
The Kinase-Independent, Second Life of CDK6 in Transcription

The Kinase-Independent, Second Life of CDK6 in Transcription
Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer
Sustaining Proliferative Signaling and Evading Growth Suppressors

Sustaining Proliferative Signaling and Evading Growth Suppressors
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies  Nima Rezaei, MD, PhD, Mona Hedayat, MD,

Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies  Nima Rezaei, MD, PhD, Mona Hedayat, MD,
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
cMET Exon 14 Skipping: From the Structure to the Clinic

cMET Exon 14 Skipping: From the Structure to the Clinic
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor  Suzanne M. Nicholl,

Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor  Suzanne M. Nicholl,
Figure 1 A schematic representation of the HER2 signalling pathway

Figure 1 A schematic representation of the HER2 signalling pathway
From mesothelioma to cardiovascular protection via the phosphoinositide-3 kinase pathway: A new vista in cardiothoracic surgery  Igor E. Konstantinov,

From mesothelioma to cardiovascular protection via the phosphoinositide-3 kinase pathway: A new vista in cardiothoracic surgery  Igor E. Konstantinov,
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Similar presentations

Ads by Google